IRTC

iRhythm Technologies Inc

Add to Watchlist

Advanced Chart

168.500

-10.62(-5.929%)1D

Line

Candle

YTD

High

184.490

Open

183.300

VWAP

172.03

Vol

653.47K

Mkt Cap

5.43B

Low

168.500

Amount

112.42M

EV/EBITDA(TTM)

Total Shares

31.10M

5.51B

EV/OCF(TTM)

74.61

P/S(TTM)

7.62

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

217.20M

+16.34%

-0.074

-76.79%

191.26M

+20.54%

-0.548

-42.35%

199.94M

+21.67%

0.059

+494.8%

Estimates Revision

The market is revising Upward the revenue expectations for iRhythm Technologies, Inc. (IRTC) for FY2025, with the revenue forecasts being adjusted by 1.67% over the past three months. During the same period, the stock price has changed by 3.95%.

Revenue Estimates for FY2025

Revise Upward

+1.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-23.12%

In Past 3 Month

Stock Price

Go Up

+3.95%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 195.46 USD with a low forecast of 175.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 168.500

Low

175.00

Averages

195.46

High

220.00

Current: 168.500

Low

175.00

Averages

195.46

High

220.00

Goldman Sachs

David Roman

Neutral

maintain

$180 -> $202

2025-11-03

Reason

Goldman Sachs

David Roman

Price Target

$180 -> $202

2025-11-03

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on iRhythm to $202 from $180 and keeps a Neutral rating on the shares.

Truist

Richard Newitter

Buy

maintain

$205 -> $230

2025-11-02

Reason

Truist

Richard Newitter

Price Target

$205 -> $230

2025-11-02

maintain

Buy

Reason

Truist analyst Richard Newitter raised the firm's price target on iRhythm to $230 from $205 and keeps a Buy rating on the shares. The company delivered a clean Q3 beat and raise result fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note. The increase in FY25 revenue guidance signals the management's confidence in broad portfolio momentum going forward, the firm added.

Oppenheimer

Outperform

maintain

$175 -> $225

2025-10-31

Reason

Oppenheimer

Price Target

$175 -> $225

2025-10-31

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on iRhythm to $225 from $175 and keeps an Outperform rating on the shares. The firm notes Q3 revenue came in at $193M, bucking the seasonal trend and ahead of its/consensus $184M/$185M estimates.

JPMorgan

Overweight

maintain

$190 -> $240

2025-10-31

Reason

JPMorgan

Price Target

$190 -> $240

2025-10-31

maintain

Overweight

Reason

JPMorgan raised the firm's price target on iRhythm to $240 from $190 and keeps an Overweight rating on the shares. The company reported "another broad-based beat" and is positioned for another year of upside in 2026, the analyst tells investors in a research note.

Goldman Sachs

David Roman

Neutral

maintain

$180 -> $202

2025-10-31

Reason

Goldman Sachs

David Roman

Price Target

$180 -> $202

2025-10-31

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on iRhythm to $202 from $180 and keeps a Neutral rating on the shares. The firm updated its model following the Q3 earnings report.

Needham

Buy

maintain

$193 -> $244

2025-10-31

Reason

Needham

Price Target

$193 -> $244

2025-10-31

maintain

Buy

Reason

Needham raised the firm's price target on iRhythm to $244 from $193 and keeps a Buy rating on the shares. The company's Q3 revenue beat consensus and management raised its 2025 revenue guidance by more than the beat, with the key drivers being Zio Monitor, further Zio AT penetration, and traction in the innovative channel, where iRhythm picked up a handful of new accounts, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for iRhythm Technologies Inc (IRTC.O) is -339.99, compared to its 5-year average forward P/E of -59.45. For a more detailed relative valuation and DCF analysis to assess iRhythm Technologies Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-59.45

Current PE

-339.99

Overvalued PE

-6.02

Undervalued PE

-112.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

189.92

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1099.40

Undervalued EV/EBITDA

-719.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.25

Current PS

168.50

Overvalued PS

27.94

Undervalued PS

-9.44

Financials

Annual

Quarterly

FY2025Q3

YoY :

+30.74%

192.88M

Total Revenue

FY2025Q3

YoY :

-52.15%

-4.90M

Operating Profit

FY2025Q3

YoY :

-88.71%

-5.21M

Net Income after Tax

FY2025Q3

YoY :

-89.19%

-0.16

EPS - Diluted

FY2025Q3

YoY :

+3808.77%

20.05M

Free Cash Flow

FY2025Q3

YoY :

+3.36%

71.09

Gross Profit Margin - %

FY2025Q3

YoY :

-129.53%

4.61

FCF Margin - %

FY2025Q3

YoY :

-91.37%

-2.70

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders areSelling! The selling amount has increased 110.72% over the last month.

Sold

0-3

Months

6.2M

USD

3-6

Months

7.9M

USD

6-9

Months

2.3M

USD

0-12

Months

7.2M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 281.11% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

294.1K

Volume

0-12

Months

77.2K

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

56.8K

Volume

Months

0-12

2.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

8.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 110.72% over the last month.

Sold

0-3

Months

6.2M

USD

3-6

Months

7.9M

USD

6-9

Months

2.3M

USD

0-12

Months

7.2M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IRTC News & Events

Events Timeline

2025-11-11 (ET)

2025-11-11

08:09:52

iRhythm Reveals Study Publication in Heart Rhythm Journal

2025-10-30 (ET)

2025-10-30

16:30:39

iRhythm Projects FY25 Revenue Between $735M and $740M, Exceeding Consensus of $726.41M

2025-10-30

16:30:01

iRhythm Announces Q3 Adjusted EPS of 6 Cents, Falling Short of Consensus Estimate of 28 Cents

News

7.0

11-12Yahoo Finance

The Impact of Favorable Clinical Results and Improved Forecast on iRhythm (IRTC)’s Position in Cardiac Monitoring

4.0

10-31Benzinga

JP Morgan Keeps Overweight Rating on iRhythm Technologies and Increases Price Target to $240

9.5

10-31Benzinga

iRhythm Poised for Success in 2026 Following Positive Results and Improved Forecast

People Also Watch

Rush Street Interactive Inc

Resideo Technologies Inc

Algonquin Power & Utilities Corp

6.150

USD

-0.16%

FAQ

What is iRhythm Technologies Inc (IRTC) stock price today?

The current price of IRTC is 168.5 USD — it has decreased -5.93 % in the last trading day.

IRTC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

IRTC News & Events

Events Timeline

News

People Also Watch

FAQ

What is iRhythm Technologies Inc (IRTC) stock price today?

What is iRhythm Technologies Inc (IRTC)'s business?

What is the price predicton of IRTC Stock?

What is iRhythm Technologies Inc (IRTC)'s revenue for the last quarter?

What is iRhythm Technologies Inc (IRTC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for iRhythm Technologies Inc (IRTC)'s fundamentals?

How many employees does iRhythm Technologies Inc (IRTC). have?

What is iRhythm Technologies Inc (IRTC) market cap?